Hatch
Medical and Rafael Medical Technologies Sign Vena Cava Filter Agreement
Atlanta, Georgia - Hatch Medical, L.L.C., a medical device
incubator and technology brokerage firm, announced today that it has recently
entered into an agreement with Rafael Medical Technologies, Inc. (Caesarea,
Israel) to broker its patented vena cava filter.
Rafael Medical's SafeFloTM,
a retrievable or optional vena cava filter for the management and prevention of
pulmonary embolism, utilizes shape memory alloys and
proprietary design elements to create a novel intravascular structure with
exceptional utility.
The use of filters implanted in the inferior vena cava is
well established for the prevention of pulmonary embolism in high-risk patients,
and are performed in approximately 80,000 cases each year in the United States.
While current devices are sufficiently effective, most vena cava filters
have limited indications since they cannot be removed, pose risks to the
patient, and many are difficult and costly to implant.
Incorporating
numerous product features previously unavailable, the SafeFloTM
filter offers a non-tilt, low-profile system (5 French) that allows for
intraprocedure repositioning and active detachment.
As a result, the SafeFlo™ filter reduces the possible risks associated
with imperfect filter positioning and potentially facilitates bedside placement
under ultrasound guidance. Additionally,
the SafeFlo™ filter utilizes a unique fixation method that can prevent vessel
damage while improving filter stability and facilitates retrieval after extended
implantation periods.
"SafeFloTM
has the opportunity to expand the use of vena cava filters on a prophylactic
basis among approximately two million patients that are potentially at risk of
developing pulmonary embolus each year in the United States.
We are very excited to be working with Rafael Medical and believe that
the SafeFlo™ filter will provide innumerable benefits and greater procedural
options for clinicians and patients by reducing the risks and costs associated
with filter placement", commented Paul Gianneschi, President and CEO of Hatch
Medical, L.L.C.
Aaron Feldman, Rafael Medical Technology's President
and C.E.O. added, "We are pleased by the enthusiasm Hatch Medical has
demonstrated towards our filter and the substantial benefits it affords to
patients and physicians. We look forward to working with Hatch Medical to secure
a partner committed to bringing this, our first, novel device to market and to
realizing the full potential of prophylactic vena cava filter use."
The
SafeFlo™ vena cava filter technology is available for licensing or strategic
marketing relationship to interested companies through an agreement with Hatch
Medical.
Hatch
Medical jointly develops and brokers minimally invasive medical devices for the
diagnosis and treatment of peripheral vascular, cardiovascular and oncological
disease states through its network of product development experts.
SafeFloTM
is under clinical investigation and is not available for sale in any country.
For additional
information on this, or other Hatch Medical, L.L.C. products and services,
e-mail the company at info@hatchmedical.com.
This release and additional news about Hatch Medical can be obtained by
visiting the company's web site at: http://www.hatchmedical.com.
Contact
Paul Gianneschi, President and CEO, 770-982-6306, or Steve Hvozda, Executive
Vice President, Business Development 404-982-9994
Hatch Medical,
L.L.C.
Duluth, GA 30097
Phone: 770-476-9940
Facsimile: 770-476-7740
info@hatchmedical.com
© 2001 - 2008 Hatch Medical, L.L.C. - All rights reserved